Conatus Pharmaceuticals Inc. (CNAT)
(Delayed Data from NSDQ)
$0.90 USD
+0.05 (5.88%)
Updated May 3, 2019 03:59 PM ET
After-Market: $0.90 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Histogen Inc. [CNAT]
Reports for Purchase
Showing records 121 - 140 ( 226 total )
Company: Histogen Inc.
Industry: Medical - Products
Company: Histogen Inc.
Industry: Medical - Products
NASH SPLASH: Highlights From Our Inaugural NASH Investor Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Histogen Inc.
Industry: Medical - Products
Agenda for Our First Annual NASH Investor Conference on April 3 in NY
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Histogen Inc.
Industry: Medical - Products
Company: Histogen Inc.
Industry: Medical - Products
4Q16 Recap: Novartis License Option for Emricasan Likely in 2Q; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Histogen Inc.
Industry: Medical - Products
Company: Histogen Inc.
Industry: Medical - Products
Company: Histogen Inc.
Industry: Medical - Products
Company: Histogen Inc.
Industry: Medical - Products
Company: Histogen Inc.
Industry: Medical - Products
Company: Histogen Inc.
Industry: Medical - Products
Company: Histogen Inc.
Industry: Medical - Products
Company: Histogen Inc.
Industry: Medical - Products
Company: Histogen Inc.
Industry: Medical - Products
Company: Histogen Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Histogen Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Histogen Inc.
Industry: Medical - Products
Emricasan-Yes-I-Can: Conatus Celebrates Year-End with a Partnership
Provider: Roth Capital Partners, Inc.
Analyst: YANIV S
Company: Histogen Inc.
Industry: Medical - Products
Conatus Enters Into Transformational Deal With Novartis; Affirm Buy, Raise PT to $18
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E